Aclaris Launched Phase 2b Trial Of Modzatinib For Lichen Planus; Stock Down

Aclaris Therapeutics (ACRS) began a Phase 2b trial for modzatinib, an oral treatment for moderate-to-severe lichen planus. The trial will enroll 100 patients, with results expected in late 2027. The FDA granted Fast Track designation to modzatinib. ACRS stock is down 8.08% in pre-market trading.

Original reporting
Published Nov 16, 2026, 12:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ACRS
Bearish
high confidence
Mentioned
$ACRS
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ACRSBearishMed
01

Why it matters

The Phase 2b launch and Fast Track status represent the first public disclosure of this program, prompting an 8% pre‑market decline.

02

Market read

First report of a mid‑stage trial for a niche dermatology indication; likely short‑term price pressure.

03

What to watch

Potential partnership or licensing deals for modzatinib could offset trial risk.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Aclaris Therapeutics (NASDAQ: ACRS) is a clinical‑stage biotech focused on inflammatory diseases.

Company-level read

Ticker impact

$ACRSBearishHigh confidence
Context

Aclaris Therapeutics announced the initiation of a Phase 2b trial of modzatinib for moderate-to-severe lichen planus.

Expected impact

likely further downside as investors price in trial risk and await data.

Evidence & confidence

New trial start and Fast Track designation introduce uncertainty; early‑stage data often moves the share price.

Market effects

adds a pipeline candidate to the dermatology/immune‑modulation biotech space.

US biotech sector may see modest pressure.

Limited; relevance confined to investors tracking early‑stage biotech trials.

Counterpoint

If the trial shows early safety signals, the stock could rebound despite the initial sell‑off.

Key entities

  • Aclaris Therapeutics

    Biotech developer of modzatinib.

Related articles

$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.

$ACRSMed

Aclaris Therapeutics Reports Phase 2 Bosakitug Miss and Advances Lichen Planus Trial

Aclaris Therapeutics reported that bosakitug failed to meet primary and secondary endpoints in its Phase 2 atopic dermatitis trial but was well tolerated. The company advanced its clinical pipeline, initiating a Phase 2b trial for modzatinib in lichen planus and planning Phase 1 and 2b trials for ATI-9494 and ATI-052, respectively, in 2027. According to the company, bosakitug showed target engagement and reduced immune-activation biomarkers.